Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

The Trump administration canceled a Biden-era plan on Friday that would have made Ozempic and other weight-loss drugs available on Medicare and Medicaid and expanded access to them for millions of Ame

The CMS has opted not to move forward with a plan that would have extended Medicare coverage to obesity drugs for millions of Americans.